Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zhanxun Wu"'
Autor:
Anil Ahsan, Mengru Liu, Yanrong Zheng, Wenping Yan, Lin Pan, Yue Li, Shijia Ma, Xingxian Zhang, Ming Cao, Zhanxun Wu, Weiwei Hu, Zhong Chen, Xiangnan Zhang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 7, Pp 1708-1720 (2021)
Stroke is considered a leading cause of mortality and neurological disability, which puts a huge burden on individuals and the community. To date, effective therapy for stroke has been limited by its complex pathological mechanisms. Autophagy refers
Externí odkaz:
https://doaj.org/article/8e876df7c57441bc8992e7b0675d43bb
Autor:
Mengru Liu, Xinyu Zhou, Yue Li, Shijia Ma, Ling Pan, Xingxian Zhang, Wanqing Zheng, Zhanxun Wu, Ke Wang, Anil Ahsan, Jiaying Wu, Lei Jiang, Yangyang Lu, Weiwei Hu, Zhenghong Qin, Zhong Chen, Xiangnan Zhang
Publikováno v:
Redox Biology, Vol 53, Iss , Pp 102323- (2022)
TP53-induced glycolysis and apoptosis regulator (TIGAR) alleviates oxidative stress and protects against ischemic neuronal injury by shifting glucose metabolism into the pentose phosphate pathway (PPP). However, the brain alters glucose metabolism fr
Externí odkaz:
https://doaj.org/article/09e71587fb2848ff9d0222ddbd32e387
Autor:
Zhanxun Wu, Wenping Yan, Ke Wang, Genghua Xu, Danyan Zhu, Xuyun Li, Huafeng Wang, Min Yang, Xiangnan Zhang, Jiaying Wu
Publikováno v:
Archives of Toxicology. 97:1385-1396
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca021773eb51d78cae081cac45e14201
https://doi.org/10.1007/s00204-023-03468-6
https://doi.org/10.1007/s00204-023-03468-6
Autor:
Zhanxun Wu, Wenping Yan, Ke Wang, Genghua Xu, Danyan Zhu, Xuyun Li, Huafeng Wang, Min Yang, Xiangnan Zhang, Jiaying Wu
Bortezomib (BTZ) is a proteasome inhibitor serves as a first-line drug for multiple myeloma treatment. BTZ-induced peripheral neuropathy (BIPN) is the most common adverse effect of BTZ with an incidence as high as 40%-60%. However, the pathological m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a029d6d0437ff9a961adcb9e7dbe1f4
https://doi.org/10.21203/rs.3.rs-2241499/v1
https://doi.org/10.21203/rs.3.rs-2241499/v1
Autor:
Mengru Liu, Shijia Ma, Yue Li, Anil Ahsan, Wenping Yan, Yanrong Zheng, Zhong Chen, Zhanxun Wu, Ming Cao, Xingxian Zhang, Weiwei Hu, Ling Pan, Xiangnan Zhang
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 7, Pp 1708-1720 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 7, Pp 1708-1720 (2021)
Stroke is considered a leading cause of mortality and neurological disability, which puts a huge burden on individuals and the community. To date, effective therapy for stroke has been limited by its complex pathological mechanisms. Autophagy refers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8275a01a7067dd1af9480fcfa0d27454
https://pubmed.ncbi.nlm.nih.gov/34386317
https://pubmed.ncbi.nlm.nih.gov/34386317
Autor:
Yuefeng Rao, Dongsheng Hong, Jiaying Wu, Zhanxun Wu, Wenping Yan, Xiangnan Zhang, Xihao Dong, Lili Huang, Lin Liu, Yuyu Zhang
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 142, Iss, Pp 112068-(2021)
The proteasome inhibitor bortezomib (BTZ) is a first-line antitumor drug, mainly used for multiple myeloma treatment. However, BTZ shows prominent toxicity in the peripheral nervous system, termed BTZ-induced peripheral neuropathy (BIPN). BIPN is cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06591a8edcb6bc0d459003e97b851da1
https://doi.org/10.1016/j.biopha.2021.112068
https://doi.org/10.1016/j.biopha.2021.112068